AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
AAPL   331.50 (+2.85%)
MSFT   187.20 (+2.34%)
FB   230.77 (+1.98%)
GOOGL   1,440.02 (+1.82%)
AMZN   2,483.00 (+0.91%)
NVDA   356.80 (+1.75%)
CGC   16.51 (-0.72%)
BABA   219.55 (+0.69%)
MU   53.72 (+4.88%)
GE   7.88 (+1.81%)
TSLA   885.66 (+2.46%)
AMD   53.10 (+0.89%)
T   32.77 (+3.05%)
ACB   13.94 (-2.04%)
F   7.34 (+5.46%)
GILD   76.75 (-1.02%)
DIS   124.82 (+0.91%)
NFLX   419.60 (+1.27%)
BAC   28.11 (+4.97%)
BA   205.43 (+11.47%)
Log in

ASX:PBTPrana Biotechnology Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume77,563 shs
Market Capitalization$27.81 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-93494906

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.34 million
Book ValueA$0.02 per share

Profitability

Miscellaneous

Employees14
Market Cap$27.81 million
Next Earnings DateN/A
OptionableOptionable

Receive PBT News and Ratings via Email

Sign-up to receive the latest news and ratings for PBT and its competitors with MarketBeat's FREE daily newsletter.

Prana Biotechnology (ASX:PBT) Frequently Asked Questions

How were Prana Biotechnology's earnings last quarter?

Prana Biotechnology Limited (ASX:PBT) posted its quarterly earnings results on Thursday, February, 28th. The biotechnology company reported ($0.01) earnings per share for the quarter. View Prana Biotechnology's earnings history.

Has Prana Biotechnology been receiving favorable news coverage?

Media stories about PBT stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Prana Biotechnology earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutPrana Biotechnology.

Who are some of Prana Biotechnology's key competitors?

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the following people:
  • Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)
  • Ms. Kathryn Andrews, Chief Financial Officer (Age 52)
  • Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)
  • Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum M.D., Chief Medical Advisor

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the ASX under the ticker symbol "PBT."

How big of a company is Prana Biotechnology?

Prana Biotechnology has a market capitalization of $0.00 and generates $4.34 million in revenue each year. Prana Biotechnology employs 14 workers across the globe.

What is Prana Biotechnology's official website?

The official website for Prana Biotechnology is pranabio.com.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is PO Box 655, MELBOURNE, VIC 3053, Australia. The biotechnology company can be reached via phone at +61-3-93494906.

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.